Citigroup Initiates Coverage On Longboard Pharmaceuticals with Buy Rating, Announces Price Target of $40
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst David Hoang initiates coverage on Longboard Pharmaceuticals (NASDAQ:LBPH) with a Buy rating and a price target of $40.

February 16, 2024 | 11:44 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Citigroup has initiated coverage on Longboard Pharmaceuticals with a Buy rating and set a price target of $40.
Analyst ratings, especially from a major financial institution like Citigroup, can significantly influence investor sentiment and stock prices. A Buy rating combined with a high price target suggests a positive outlook for Longboard Pharmaceuticals, potentially leading to increased investor interest and a rise in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100